quinagolide (Norprolac) Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Quinagolide (INNTooltip International nonproprietary name, BANTooltip British Approved Name), sold under the brand name Norprolac, is a selective dopamine D2 receptor agonist which is used to reduce elevated levels of prolactin (hyperprolactinemia). It has also been found to be effective in the treatment of breast pain. It is used in the UK, but it is not available in US.   Wikipedia

Chemistry

  • SMILES: CCCN1CC(NS(=O)(=O)N(CC)CC)CC2Cc3c(O)cccc3CC21
  • InChIKey: GDFGTRDCCWFXTG-UHFFFAOYSA-N
  • Mol. Mass: 395.57
  • ALogP: 2.14
  • ChEMBL Molecules:
    quinagolide  
    quinagolide  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$2.1646
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

cv 205-502 | cv-205-502 | cv205-502 | n,n-diethyl-n'-(1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propyl-3-benzo(g)quinolinyl)sulfamide, (3alpha,4aalpha,10abeta)-(+-)-isomer | n,n-diethyl-n'-(1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propyl-3-benzo(g)quinolinyl)sulfamide hydrochloride, (3alpha,4aalpha,10abeta)-(+)-isomer | (+-)-n,n-diethyl-n'-((3r*,4ar*,10as*)-1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propylbenzo(g)quinolin-3-yl)sulfamide | norprolac | quinagolida | quinagolide | quinagolide, (3alpha,4aalpha,10abeta)-(+-)-isomer | quinagolide hydrochloride | quinagolide hydrochloride, (3alpha,4aalpha,10abeta)-(+)-isomer | quinagolide hydrochloride, 3alpha,4aalpha,10abeta-(-)-isomer | quinagolidum | sdz 205-502

Organizations (3)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (1)


 

Hyperprolactinemia

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Endometriosis (Phase 2)

Hyperprolactinemia ()

Ovarian Hyperstimulation Syndrome (Phase 2)

Pain (Phase 2)

Pituitary Neoplasms (Phase 4)

Prolactinoma (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue